In this context, the restoring of FGF21 signaling can be considered as a potential therapeutic strategy to improve the metabolic parameters of obese individuals and to reduce the risk of obesity-related diseases and some evidence support this hypothesis [7,109]. This evidence concerns the gene FGF21 and glycogen storage disease VI.